NDAORALSOLUTION
Approved
Oct 2025
Lifecycle
Launch
Competitive Pressure
0/100
Data completeness
4/8 — Partial
JAVADIN (clonidine hydrochloride oral) by R-Pharm US is alpha-adrenoreceptors in the brain. Approved for hypertension in adult patients to lower blood pressure, hypertension. First approved in 2025.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JAVADIN is an oral solution formulation of clonidine hydrochloride, a centrally-acting alpha-adrenoreceptor agonist approved for hypertension in adult patients. It reduces blood pressure by stimulating alpha-adrenoreceptors in the brainstem, decreasing sympathetic outflow and peripheral vascular resistance. This is a newly approved (October 2025) branded generic oral solution in the established antihypertensive market.
Launch16.2 years to LOE
JAVADIN launches into a mature, competitive hypertension market with zero competitive pressure currently, positioning early teams for aggressive market capture but requiring differentiation through formulation advantage and payer relationships.
Mechanism of Action
alpha-adrenoreceptors in the brain. Clonidine is not a central nervous system stimulant. Clonidine is a known antihypertensive agent. By stimulating alpha-adrenoreceptors in the brain stem, clonidine reduces sympathetic outflow from the central nervous system and decreases peripheral resistance,…
Worked on JAVADIN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.